Neurogene (NASDAQ:NGNE) & CytoMed Therapeutics (NASDAQ:GDTC) Head-To-Head Survey

CytoMed Therapeutics (NASDAQ:GDTC) and Neurogene (NASDAQ:NGNE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, risk and profitability.

Institutional and Insider Ownership

0.0% of CytoMed Therapeutics shares are owned by institutional investors. Comparatively, 52.4% of Neurogene shares are owned by institutional investors. 11.7% of Neurogene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk & Volatility

CytoMed Therapeutics has a beta of -0.05, meaning that its stock price is 105% less volatile than the S&P 500. Comparatively, Neurogene has a beta of 1.69, meaning that its stock price is 69% more volatile than the S&P 500.

Profitability

This table compares CytoMed Therapeutics and Neurogene’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CytoMed Therapeutics	N/A	N/A	N/A
Neurogene	N/A	-37.88%	-34.70%

Valuation & Earnings

This table compares CytoMed Therapeutics and Neurogene”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytoMed Therapeutics	$250,000.00	48.74	-$3.10 million	N/A	N/A
Neurogene	$930,000.00	510.87	-$90.35 million	($4.55)	-6.61

CytoMed Therapeutics has higher earnings, but lower revenue than Neurogene.

Analyst Ratings

This is a summary of current ratings and price targets for CytoMed Therapeutics and Neurogene, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytoMed Therapeutics	1	0	0	0	1.00
Neurogene	1	0	3	2	3.00

Neurogene has a consensus target price of $84.83, suggesting a potential upside of 182.12%. Given Neurogene’s stronger consensus rating and higher probable upside, analysts clearly believe Neurogene is more favorable than CytoMed Therapeutics.

Summary

Neurogene beats CytoMed Therapeutics on 9 of the 12 factors compared between the two stocks.

About CytoMed Therapeutics

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.

About Neurogene

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.